source
- Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular diseaseVaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program. The capital will support a newly launched Phase 3 study of the oral dr…
- BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme assetBioMarin announced it will stop development of BMN 401, an enzyme replacement therapy acquired in its $270 million purchase of Inozyme Pharma. The decision follows the Phase 3 ENERGY trial in pati…